Pfizer Inc. $PFE Holdings Increased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 62.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,721,719 shares of the biopharmaceutical company’s stock after acquiring an additional 1,820,944 shares during the quarter. Pictet Asset Management Holding SA owned about 0.08% of Pfizer worth $134,667,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of PFE. TOWER TRUST & INVESTMENT Co increased its position in Pfizer by 1.9% during the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 357 shares during the last quarter. Angeles Wealth Management LLC boosted its holdings in shares of Pfizer by 2.2% in the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 358 shares during the last quarter. Manchester Financial Inc. boosted its holdings in shares of Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 365 shares during the last quarter. Signature Equity Partners LLC grew its stake in shares of Pfizer by 22.9% during the 3rd quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 385 shares during the period. Finally, Delta Financial Advisors LLC grew its stake in shares of Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Scotiabank increased their target price on Pfizer from $33.00 to $35.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, November 4th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. JPMorgan Chase & Co. upped their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Argus set a $40.00 price objective on Pfizer in a report on Wednesday. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Six analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $30.39.

Pfizer Price Performance

PFE opened at $29.38 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $31.44. The company has a 50 day moving average of $28.74 and a two-hundred day moving average of $26.90. The company has a market cap of $167.47 billion, a P/E ratio of 41.97, a P/E/G ratio of 1.93 and a beta of 0.31.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The business had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter last year, the firm posted $0.87 EPS. The business’s revenue for the quarter was down .4% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 3.04 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is currently 245.71%.

About Pfizer